Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

Similar articles for PubMed (Select 23981744)

1.

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.

Yeo SI.

Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 Apr 26. Review.

PMID:
23981744
2.

HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.

Cheng L, Xiong Y, Qin CZ, Zhang W, Chen XP, Li J, Zhou HH.

Br J Dermatol. 2015 Mar 2. doi: 10.1111/bjd.13688. [Epub ahead of print] No abstract available.

PMID:
26104483
3.

Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield M, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT.

Clin Pharmacol Ther. 2015 Jun 10. doi: 10.1002/cpt.161. [Epub ahead of print]

PMID:
26094938
4.

A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout.

Roberts RL, Wallace MC, Harrison A, Dalbeth N, Merriman TR, Stamp LK.

Pharmacogenet Genomics. 2015 Jun 5. [Epub ahead of print]

PMID:
26049586
5.

Viruses may trigger allopurinol hypersensitivity syndrome.

Koike M, Kanno Y, Tomori K, Okada H, Suzuki H.

NDT Plus. 2008 Aug;1(4):273-4. doi: 10.1093/ndtplus/sfn042. No abstract available.

6.

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.

Jarjour S, Barrette M, Normand V, Rouleau JL, Dubé MP, de Denus S.

Pharmacogenomics. 2015 May;16(7):755-67. doi: 10.2217/pgs.15.21. Epub 2015 May 12.

PMID:
25965122
7.

Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.

Chung WH, Pan RY, Chu MT, Chin SW, Huang YL, Wang WC, Chang JY, Hung SI.

J Invest Dermatol. 2015 May 6. doi: 10.1038/jid.2015.165. [Epub ahead of print]

PMID:
25946710
8.

Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.

Caldarola G, Sollena P, Peris K, De Simone C.

J Dermatol. 2015 Jul;42(7):753-4. doi: 10.1111/1346-8138.12894. Epub 2015 Apr 20. No abstract available.

PMID:
25899558
9.

Pharmacogenetic considerations in the treatment of gout.

Roberts RL, Stamp LK.

Pharmacogenomics. 2015;16(6):619-29. doi: 10.2217/pgs.15.16. Epub 2015 Apr 16.

PMID:
25876828
10.

Allopurinol induced stevens - johnson syndrome - a case report.

Paik S, Sen S, Das J, Saha B, Tripathi SK.

J Clin Diagn Res. 2015 Feb;9(2):WJ01-2. doi: 10.7860/JCDR/2015/11786.5558. Epub 2015 Feb 1. No abstract available.

11.

Role of dermatology in pharmacogenomics: drug-induced skin injury.

Borroni RG.

Pharmacogenomics. 2015;16(4):401-12. doi: 10.2217/pgs.15.4.

PMID:
25823788
12.

An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing.

Jung JW, Kim DK, Park HW, Oh KH, Joo KW, Kim YS, Ahn C, Lee KW, Cho SH, Min KU, Kang HR.

Genet Med. 2015 Jan 29. doi: 10.1038/gim.2014.195. [Epub ahead of print]

PMID:
25634024
13.

Drug eruptions induced by allopurinol associated with HLA-B*5801.

Zeng M, Zhang M, Liu F, Yan W, Kong Q, Sang H.

Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):43-5. doi: 10.4103/0378-6323.148566.

14.

Mixed signals: toxic epidermal necrolysis.

Villano JH, Lovell EO.

Am J Med. 2015 Mar;128(3):254-6. doi: 10.1016/j.amjmed.2014.11.004. Epub 2014 Nov 18. No abstract available.

PMID:
25460525
15.

Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.

Lin CH, Chen JK, Ko TM, Wei CY, Wu JY, Chung WH, Chen SY, Liao YD, Hung SI, Chen YT.

J Allergy Clin Immunol. 2015 Apr;135(4):1063-5.e5. doi: 10.1016/j.jaci.2014.09.041. Epub 2014 Nov 11. No abstract available.

PMID:
25458913
16.

[Allopurinol hypersensitivity syndrome: Liver transplantation after treatment of asymptomatic hyperuricaemia].

Miederer SE, Miederer KO.

Dtsch Med Wochenschr. 2014 Dec;139(49):2537-40. doi: 10.1055/s-0034-1387408. Epub 2014 Nov 25. German.

PMID:
25423467
17.

Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing.

Janssens AC, Deverka PA.

Clin Pharmacol Ther. 2014 Dec;96(6):652-4. doi: 10.1038/clpt.2014.186. No abstract available.

PMID:
25399713
18.

T cell-mediated hypersensitivity reactions to drugs.

Pavlos R, Mallal S, Ostrov D, Buus S, Metushi I, Peters B, Phillips E.

Annu Rev Med. 2015;66:439-54. doi: 10.1146/annurev-med-050913-022745. Epub 2014 Oct 27.

19.

Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity.

Lee MT, Mahasirimongkol S, Zhang Y, Suwankesawong W, Chaikledkaew U, Pavlidis C, Patrinos GP, Chantratita W.

Public Health Genomics. 2014;17(5-6):248-55. doi: 10.1159/000366253. Epub 2014 Oct 21. Review.

PMID:
25341524
20.

Personalized medicine approaches in epilepsy.

Walker LE, Mirza N, Yip VL, Marson AG, Pirmohamed M.

J Intern Med. 2015 Feb;277(2):218-34. doi: 10.1111/joim.12322. Review.

PMID:
25338670
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk